SP13: Biologic risk factors

Knowledge of biological markers with prognostic impact is of high value. It helps us to intuit the evolution of the disease, to calculate the patient's chances of survival, to stratify patients into different groups, to consider the possibilities of relapse, to evaluate the benefit of administering a specific treatment and the response to the same, to compare different treatments and to design clinical trials.
In contrast to acute leukaemia, the prognostic impact of biologic parameters in malignant lymphomas is still poorly understood despite significant progress in our knowledge of molecular events leading to the development of the disease. The key goal of the proposed project is to provide an optimised infrastructure for the collection of fresh tumour tissue and to create a closer interaction between clinicians and reference pathologists on the one hand and scientists involved in the research into biologic risk parameters on the other hand.

» Contact Persons